ACLA Wins in Appeals Court Versus HHS

Recently, the DC Court of Appeals determined that federal courts do in fact “have jurisdiction to decide the merits of a challenge to the federal government’s administration of the Protecting Access to Medicare Act (PAMA).”1 This ruling will result in the ACLA vs. Azar case being sent back to the DC District Court to determine if the decision from HHS/CMS to exclude hospital outreach labs from...

Read


The Value of a Patient to Payment Process for Next-Gen Sequencing and Pharmacogenomics

The volume of next-generation sequencing (NGS) and pharmacogenomics (PGx) tests is growing every year. According to the Next Generation Sequencing Market Report published by Allied Market Research, the global NGS market is expected to reach $12.8 billion by 20221. These are high-value tests in terms of both diagnostic worth and cost. As such, laboratories need to understand the pathway to...

Read


4 Reasons Your Lab Should Use Automated Bank Reconciliation

In a recent blog post titled “How the Most Successful Laboratories in the Country Continue to Thrive in the Midst of an Increasingly Complex Reimbursement Environment,” XIFIN Vice President of Sales, Steve Neilson discussed the importance of real-time visibility and business intelligence for laboratories. Laboratory revenue cycle management (RCM) solutions that are interoperable and are designed...

Read


“Big Data” Can Be a Big Threat – If You’re Not Prepared to Control It

Enjoy the following content from our strategic partner, U.S. Healthtek. Imagine a day where “Big Data” isn’t some abstract concept that costs you money and resources, but is a vital component to your lab’s success as a source of revenue.Well, that day was yesterday. Competitors now understand that the abundance of data is meaningless unless you know how to manage...

Read


Are You Taking Control of Your Lab RCM?

On July 18th in Boston, I had the opportunity to attend G2 Intelligence’s Lab Leadership Summit: Designing, Implementing & Managing a High-Profit Lab Outreach Program. This conference consisted of a variety of attendees from hospital lab directors and outreach managers, to consultants and industry partners, all connecting with the common goal of discovering how to maximize operational...

Read


ACLA Issued a Statement to CMS on Automated Chemistry Test Panels

After claims from the Government Accountability Office (GAO) in November of 2018 that labs unbundling automated chemistry test claims will correlate to a drastic increase in Medicare spending, many industry thought leaders are responding. Most recently, ACLA has released a statement claiming that GAO’s assumptions are not backed by Medicare’s public claims data, or by ACLA’s own survey conducted...

Read


Market Disruption is the New Normal in the Diagnostic Industry

The laboratory and diagnostics industry has experienced tremendous changes in recent years. Top of mind, of course, is PAMA. With cuts totaling up to 30% over the next three years underway, laboratories are operating in one of the most challenging environments seen to date. As had been predicted, labs have had to tighten up their operations to mitigate the lost revenues. Some labs have already...

Read


The 5 Keys to Minimizing the Impact of PAMA

At this year's Executive War College Conference, XIFIN CEO and Executive Chairman, Lâle White presented on PAMA’s effects on laboratories and gave some thought-provoking ideas on how labs can respond. This blog post will cover many of the topics that Lâle discussed, starting with this timeline of industry events which provides background on the laboratory reimbursement environment...

Read